ASCO GU 2021 Prostate Cancer - Results from #60

Viewing 61-80 of 83 articles

ASCO GU 2021: CheckMate 9KD Arm B Final Analysis: Efficacy and Safety of Nivolumab Plus Docetaxel For Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2021: Biomarker Analysis from a Randomized Phase II Study of Olaparib with or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2021: A Prospective Phase II/III Study of PSMA-Targeted 18F-DCFPyL-PET/CT in Patients with Prostate Cancer (PCa) (OSPREY): A Subanalysis of Disease Staging Changes in PCa Patients with Recurrence or Metastases on Conventional Imaging

ASCO GU 2021: Cabazitaxel Multiple Rechallenge in Metastatic Castration-Resistant Prostate Cancer: A Therapeutic Option to Increase Overall Survival?

ASCO GU 2021: Molecular Determinants Associated with Long-Term Response to Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

ASCO GU 2021: Final Results from ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate plus Prednisone (AAP) Versus AAP in Patients with Chemo-Naive Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2021: Survival Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Real-World Evidence Study

ASCO GU 2021: PARP Inhibitors – Is It A Sea Change or Just Another Incremental Change?

ASCO GU 2021: 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel: Updated Results Including Progression-Free Survival and Patient-Reported Outcomes (TheraP ANZUP 1603)

ASCO GU 2021: Active Surveillance in 2021 and Beyond

ASCO GU 2021: Olaparib Efficacy in Patients with Metastatic Castration-Resistant Prostate Cancer Carrying Circulating Tumor DNA Alterations in BRCA1, BRCA2 or ATM: Results from the PROfound Study

ASCO GU 2021: Welcome to the Wild West: The Impact of the FDA Approval of PSMA PET/CT on Prostate Cancer Management

ASCO GU 2021: Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the Detection, Intra-Prostatic Localization, and Local Extension of Primary Prostate Cancer: A Single-Center Imaging Study With Histopathology Gold-Standard

ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence

ASCO GU 2021: Safety of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer From Extended Follow-Up in the Phase III ARAMIS Trial

ASCO GU 2021: Concordance of BRCA1, BRCA2, and ATM Mutations Identified in Matched Tumor Tissue and Circulating Tumor DNA in Men with Metastatic Castration-Resistant Prostate Cancer Screened in the PROfound Study

ASCO GU 2021: ARTO Trial: A Randomized Phase II Trial Enrolling Oligometastatic CRPC Patients Treated with First-Line Abiraterone Acetate with or without Stereotactic Body Radiation Therapy

ASCO GU 2021: Efficacy of Enzalutamide plus ADT in Men with De Novo (M1) mHSPC Versus Progression to mHSPC: Post Hoc Analysis of the Phase III ARCHES Trial

ASCO GU 2021: Efficacy of the PD-L1 Inhibitor Avelumab in Neuroendocrine or Aggressive Variant Prostate Cancer: Results From a Phase II, Single-Arm Study

ASCO GU 2021: Olaparib Efficacy in Patients with Metastatic Castration-Resistant Prostate Cancer Carrying Circulating Tumor DNA Alterations in BRCA1, BRCA2 or ATM: Results from the PROfound Study

1
2
3
4
5